Article
Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens.
Molecular cancer therapeutics - 1 Apr 2007
Daniele Lorenzo, Macrì Luigia, Schena Marina, Dongiovanni Diego, Bonello Lisa, Armando Enrico, Ciuffreda Libero, Bertetto Oscar, Bussolati Gianni, Sapino Anna
Abstract excerpt
In non-small cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) mutational analysis is an excellent predictor of responsiveness to treatment with tyrosine kinase inhibitors, such as gefitinib. In up to 80% of NSCLCs, cytologic samples or endoscopic biopsies are the only specimens available for molecular analysis, but PCR amplification of DNA from small fixed and paraffin-embedded samples may create...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.